Location: Boston/Remote

The Vice President (VP), Business Development will be an experienced and accomplished Business Development professional, bringing to Aveo a portfolio of successful deal experience in the oncology space. This role’s primary accountability is to strengthen the Aveo portfolio by identifying, assessing, recommending and executing licensing, partnering, clinical collaborations and M&A opportunities.

Responsibilities (include, but are not limited to):

  • Strengthen the Company’s portfolio through licensing, partnering clinical collaboration and M&A related activities
  • Identify and lead x-US strategic partnership or out licensing opportunities with biotech and pharmaceutical companies for the companies 4 wholly owned mAb candidates
  • Lead all business development activities and due diligence which includes valuation modeling, partner outreach, and managing technical and business due diligence processes
  • Cultivate strong and effective cross-functional partnerships to evaluate potential new product in licensing opportunities that synergize with the existing portfolio and/or leverage our commercial infrastructure with the goal towards value creation
  • Establish and maintain strong alliance relationships and ensure appropriate partner diligence/engagement through effective communication and clearly setting expectations
  • Monitor and report on competitive intelligence by keeping up to date on market trends, competitors and opportunities
  • Keep abreast of research and development in areas of focus for Aveo products and pipeline
  • Understand, synthesize and effectively represent the Aveo’s corporate messaging, platform, R&D programs, targets, therapeutic approach, and vision
  • Bring value as an active contributor to the Company’s Management Leadership Team
  • Other duties and responsibilities as required


  • Bachelor’s Degree required. Advanced degree in scientific/medical discipline and/or MBA strongly preferred• 10 + years in a commercial phase multi-national pharmaceutical/biotech company with a minimum   5 years in a leadership role overseeing Corporate/Business Development is required
  • Additional experience in one or more of the following areas is strongly preferred: R&D, Commercial Operations, Technical Operations, Corporate Finance, etc.
  • Experience in the Oncology space required
  •  Meticulous organization and implementation skills
  • Strong strategic thinker & planner
  • Solid business and financial acumen
  •  Strong interpersonal skills, able to lead by influence
  • Exceptional communications & presentation skills
  • Hands-on self-starter who thrives in a rapid-paced, changing business environment
  • Extensive experience in negotiations, valuation, in/out licensing, corporate finance and deal structuring required
  • Diverse and solid business development network


  • Periodic travel to various scientific conferences and meetings with academic labs, CROs, other biotech/pharmaceutical companies and investors/analysts

Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties, or responsibilities that are required of an employee for this job. Duties, responsibilities, and activities may change at any time with or without notice.

About AVEO

AVEO Pharmaceuticals is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO’s strategy is to focus its resources on development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO’s lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (Anti-HGF/c-MET IgG1 mAb) in head and neck cancer, acute myeloid leukemia and pancreatic cancer and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab in head and neck cancer. AVEO’s earlier-stage pipeline includes several monoclonal antibodies in oncology development, including AV-203 (Anti-ERBB3 mAb), AV-380 (Anti-GDF15 IgG1mAb) and AV-353 (Anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion as a foundation for innovation.

Ficlatuzumab, AV-203, AV-380 and AV-353 are investigational drugs and have not yet been approved by the U.S. Food and Drug Administration (FDA).

Apply Now